Tigermed reports nine-month revenue growth of 15.23%
Regulatory / securities filing · 泰格医药 / 巨潮资讯 CNinfo
Source published: · Event / reporting date: 2026-09-30
Site published: 2026-11-03 · Updated: 2026-11-03
This source is linked automatically. Choose a question to get started.
What changed
Tigermed reported consolidated revenue of RMB5.792 billion, up 15.23%, and an attributable net loss of RMB272.0 million for the nine months ended September 30, 2026. Profit excluding nonrecurring items reached RMB450.1 million, up 38.08%; investment losses weighed on reported earnings. The quarterly filing is unaudited and covers the year-to-date period.
Why it may matter
Service operations and investment results diverged. The group includes Frontage, so adding their reported revenue would double count.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections